Life-threatening reversible bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab.

Autor:	Marchesoni A; Rheumatology, G. Pini Orthopaedic Institute and S. Paolo Hospital, Internal Medicine I, Milan, Italy., Arreghini M; Rheumatology, G. Pini Orthopaedic Institute and S. Paolo Hospital, Internal Medicine I, Milan, Italy., Panni B; Rheumatology, G. Pini Orthopaedic Institute and S. Paolo Hospital, Internal Medicine I, Milan, Italy., Battafarano N; Rheumatology, G. Pini Orthopaedic Institute and S. Paolo Hospital, Internal Medicine I, Milan, Italy., Uziel L; Rheumatology, G. Pini Orthopaedic Institute and S. Paolo Hospital, Internal Medicine I, Milan, Italy.
Jazyk:	angličtina
Zdroj:	Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2018 Jun 01; Vol. 57 (6), pp. 1128.
DOI:	10.1093/rheumatology/key094
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu